Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid Arthritis
Status:
Completed
Trial end date:
2018-06-25
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of
JTE-051 administered for 12 weeks in subjects with active rheumatoid arthritis who are
receiving background non-biologic disease-modifying anti-rheumatic drug therapy.